What is Tirzepatide?
Tirzepatide is an innovative medication that has garnered attention for its effectiveness in aiding weight loss. Originally developed for the treatment of Type 2 diabetes, Tirzepatide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, which mimics the effects of hormones that regulate appetite and glucose metabolism. By enhancing insulin secretion and promoting a feeling of fullness, this medication helps individuals manage their weight effectively.
Weight Loss Treatment
At Moov Labs, we are excited to offer Tirzepatide as part of our weight loss program. This treatment is designed for individuals who struggle with obesity or weight management. Patients typically experience significant weight loss when combined with a healthy diet and exercise regimen. Regular monitoring and support from our wellness team will ensure optimal results.
Adverse Reactions
While Tirzepatide can be an effective tool for weight loss, it is essential to be aware of potential adverse reactions. Common side effects may include:
- Tremors*
- Flushes*
- Fainting/Dizziness
- Unexplained Anxiety
- Chills/Fever
- Hypoglycemia
- Vision Changes/Impairment
- Burping
- Jaundice
- Cramps*
- Anaphylaxis
- Severe Headache
- Nausea
- Unexplained Irritability
- Gauntness
- Color Blindness
- Rash/Itching
- Stool Discoloration
- Difficulty Breathing*
- Angiodema*
- Diarrhea
- Vomiting
- Constipation
- Abdominal Pain
- Irregular Hunger
- Irregular Weakness
- Heart Rate Changes
- Loss of Appetite
- Retinopathy
- Blurred Vision
- Heartburn
- Swelling of Face, Eyes, Mouth
- Swelling of Legs, Ankles, Feet
Serious but less common side effects can also occur, such as:
- Pancreatitis
- Kidney problems
- Allergic reactions (rash, itching, swelling)
- Increased heart rate
*Denotes potential Tirzepatide toxicity (allergic hypersensitivity). Follow emergency protocol.
Patients are encouraged to report any unusual symptoms to our medical team immediately.
Telehealth Consultations
To ensure the safe and effective use of Tirzepatide, Moov Labs requires a telehealth consultation every three months. During these consultations, our healthcare professionals will evaluate your progress, monitor any potential side effects, and make necessary adjustments to your treatment plan. This ongoing support helps maximize the benefits of Tirzepatide while minimizing risks.
Importance of BMI
Before starting Tirzepatide treatment, it is crucial to assess your Body Mass Index (BMI). This measurement helps determine whether you qualify for the medication based on established guidelines. A BMI of 30 or higher qualifies as obese, while a BMI of 27 or higher may also be eligible if there are related health conditions. Maintaining an appropriate BMI is vital to the effectiveness of Tirzepatide and overall weight management success.
Semaglutide Disclaimer
By offering compounded drug products containing semaglutide you acknowledge and agree with the following statements:
- These products are compounded drug products containing semaglutide. They are not Ozempic, Wegovy, or Rybelsus, which are FDA approved and commercially available drug products manufactured by Novo Nordisk.
- You will not market or advertise the products as Ozempic, Wegovy, or Rybelsus or suggest any association with those products or with Novo Nordisk.
- You will not market or advertise the products as being approved by FDA, reviewed by FDA for safety, effectiveness, or quality, or demonstrated to FDA to be safe and effective for their intended use.
- You will not make any claims or suggest in any way that the products are proven to achieve certain therapeutic results or effects.
- These products may only be administered to the individual patient for which they were compounded following a good faith examination and pursuant to a practitioner’s order.
- You understand that compounded drug products such as Semglutide are not FDA approved but are able to be compounded in certain circumstances. Compounding of these products is permitted because Ozempic and Wegovy are currently listed on the FDA Drug Shortages List. If that regulatory status changes, then the availability of compounded drug products containing Semaglutide may change.
For additional information, see the below resources:
a. FDA Press Release, Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss (October 31, 2023)
b. Novo Nordisk Company Statement, Novo Nordisk takes additional legal actions to help protect US patients from potentially unsafe and ineffective compounded drugs claiming to contain semaglutide that are not FDA approved (November 29, 2023)
